SCM
DSGN icon

Sterling Capital Management’s Design Therapeutics DSGN Stock Holding History

Sterling Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.42K Sell
791
-586
-43% -$5.93K ﹤0.01% 2469
2025
Q4 		$12.9K Sell
1,377
-271
-16% -$2.12K ﹤0.01% 2481
2025
Q3 		$12.4K Buy
1,648
+807
+96% +$4.04K ﹤0.01% 2379
2025
Q2 		$2.83K Buy
841
+299
+55% +$1.12K ﹤0.01% 2808
2025
Q1 		$2.09K Sell
542
-463
-46% -$2.21K ﹤0.01% 2579
2024
Q4 		$6.2K Buy
1,005
+903
+885% +$5.23K ﹤0.01% 2360
2024
Q3 		$549 Buy
+102
New +$480 ﹤0.01% 2825

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sterling Capital Management's DSGN Position: Q1 2026 in Review

Sterling Capital Management reduced its Design Therapeutics (DSGN) stake by 43% in Q1 2026, selling an estimated $5.93K and leaving 791 shares worth $8.42K. The position accounts for ﹤0.01% of the portfolio, ranked #2469.

Sterling Capital Management first reported a position in DSGN in Q3 2024 and has held it in 7 quarters since. The position peaked at $12.9K in Q4 2025. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Sterling Capital Management held 791 shares of Design Therapeutics worth $8.42K as of Q1 2026.
  • Sterling Capital Management sold 586 Design Therapeutics shares in Q1 2026, an estimated $5.93K.
  • Design Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2469 holding.
  • Sterling Capital Management first reported a position in Design Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Design Therapeutics position peaked at $12.9K in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.